Nice upgrade and the price held up today! It looks like management were being overly conservative with their earnings forecast which kept a lid on the SP until now. If the FY19 interest/depreciation/amortisation are in the ballpark of the 2018AGM forecast we should see an FY19 underlying NPAT around $23m and EPS of approx. 5.4c, giving us a P/E of around 12 times at today's SP. Not bad for a company growing it's EBITDA at 35%+!
@hfrench, I think you are overly pessimistic in your view that PEA should be valued at low multiples;
PEA took a hit of about $4.8m in acquisition costs and $9.8min impairments in their 'reported' FY18 results, so the likelihood of more oneoff costs related to the Contract Power acquisition, which was completed in 2Q/2018, in FY19 is remote IMO.
The Petra broker report forecast FCF of about $30m p/a for the next 3 years (and that was based on a forecast FY19 EBITDA of $55m and NPAT of $20m), for a FCF yield of 12%, so it should spin off plenty of cash going forward, sufficient to pay off most the existing debt if they choose to.
Not that I consider the current gearing to be excessive,with a forecast FY19 interest cover of 14x and a D/E of 63%, an overall cost of funds of 4.25% and a RoC of 10% I would be happy to see a reasonable level of gearing maintained, say around 50% D/E.
Once the analysists recomp their forecasts based on the increased earnings I think we will see their SP targets move up from the current consensus of 72c to 75c+, and as It looks like we will see a HY dividend I’m looking to an easy 70c after the release of the HY report on Friday 22nd.
- Forums
- ASX - By Stock
- PEA
- Ann: PEA Half-Year Result Release Date & EBITDA Guidance Increase
Ann: PEA Half-Year Result Release Date & EBITDA Guidance Increase, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PEA (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.09 |
Change
0.005(0.46%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
$1.09 | $1.09 | $1.09 | $80.13K | 73.80K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 20979 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.09 | 93741 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 42510 | 0.620 |
1 | 20000 | 0.580 |
1 | 5000 | 0.550 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.630 | 12637 | 1 |
0.640 | 36649 | 2 |
0.645 | 7751 | 1 |
0.650 | 20578 | 2 |
0.655 | 8750 | 1 |
Last trade - 13.41pm 24/09/2019 (20 minute delay) ? |
Featured News
PEA (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online